Abstract Library

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: McNamara M

Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,

#1009 Streptozotocin-Based Chemotherapy is Still Alive in Patients with Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival

Introduction: Chemotherapy with Streptozotocin (STZ) and 5-FU or Doxorubicin (Doc) represents a standard of care for patients with well-differentiated metastatic neuroendocrine neoplasms, especially for the pancreas (PNENs). However, data to identify predictive and prognostic markers are limited.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Krug S, Boch M, Rinke A, Müller D, König A,

Keywords: streptozotocin, NEN, 5-fluorouracil, Doc,

#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment

Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Dilz L

Authors: Dilz L, Denecke T, Arsenic R, Steffen I, Pape U,

Keywords: pancreatic NET, Ki-67, chemotherapy, streptozotocin,

#990 Prolonged Progression-Free Survival with Extended Cycle Streptozotozin/5-FU Chemotherapy in Patients with Metastatic Pancreatic Neuroendocrine Tumors

Introduction: The treatment of pancreatic neuroendocrine tumors with streptozotocin-based chemotherapy is well-established.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Schrader J, Zimmermann-Fraedrich K, Benten D, Pace A, Bläker M,

Keywords: chemotherapy,

#888 Capecitabine (Cp) and Somatostatine Analog (SSA) Suitable Treatment for Progressing G1-G2 Neuroendocrine Tumors (WD NET)

Introduction: Results from phase II and non-randomized trials with metronomic 5-FU in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Marconcini R, Galli L, Antonuzzo A, Bracco E, Farnesi A,

Keywords: capecitabine,